|
KMID : 0614620080510060338
|
|
Korean Journal of Gastroenterology
2008 Volume.51 No. 6 p.338 ~ p.345
|
|
|
Management of Chronic Hepatitis B in Treatment-Naive Patients
|
|
Cheong Jae-Youn
|
|
|
Abstract
|
|
|
Chronic hepatitis B (CHB) is a serious health problem in Korea. The natural history of chronic HBV infection
has been divided into 4 phases: immune tolerance, immune clearance, inactive HBsAg carrier state and
reactivation. During the phases of immune tolerance and inactive HBsAg carrier state, no treatment is required.
Patients in the immune clearance or reactivation phases are candidates for therapy. In the last years, treatment effects
of CHB have considerably improved. Several agents are currently approved for the treatment of CHB: interferon
alpha, pegylated interferon alpha, lamivudine, adefovir, entecavir, telbivudine and clevudine in Korea. The
treatment recommendations from the 2004 Korean Association for the Study of the Liver guideline on the management
of CHB have been updated to incorporate new therapeutic options. What is uncertain is which agent or
combination of agents is most effective, how long therapy should last, and which criteria should be used to start,
continue, switch or stop therapy. Issues for consideration include efficacy, safety and incidences of resistance, and
method of administration of antiviral therapy in treatment-naive patients.(Korean J Gastroenterol 2008;51:338-345)
|
|
|
KEYWORD
|
|
|
Chronic hepatitis B, Treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|